AsclepiX Therapeutics
Josh Barer is Managing Director of Hibiscus BioVentures, as well as Barer & Son Capital, LLC which forms, restructures and funds early-stage cutting edge biotechnology companies.
Prior to HB and B&S, Josh has spent his career at several boutique investment banks and consultancies, including Trout Capital and the Maxim Group, and has a passion for early-stage drug development to serve patients with unmet medical needs. He is also a Venture Advisor at the Israel Biotech Fund.
Josh is on the boards of Asclepix, Inc. and NexImmune, Inc. (board observer). He is also on the Boards of several-not for-profit organizations focused on education and economic development, including Trickle Up, Family Promise, and Getting Out and Staying Out (Action Board).
Josh received a Bachelor of Arts from Rutgers College and studied Conflict Management at Drew University.
This person is not in the org chart
This person is not in any offices
AsclepiX Therapeutics
1 followers
AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways. Their peptide drug candidates tap into the body’s powerful mechanisms of maintaining homeostasis, the fundamental principle of biology to seek and maintain a condition of equilibrium or stability.